Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

NICE Recommends Gedeon Richter’s Ryeqo for Uterine Fibroids
NICE Recommends Gedeon Richter’s Ryeqo for Uterine Fibroids
The UK’s National Institute for Health and Care Excellence (NICE) is recommending Gedeon Richter’s Ryeqo (relugolix, estradiol and norethisterone acetate) for National Health Service use for t...
Lilly’s new drug Mounjaro (tirzepatide ) wins US FDA approval
Lilly’s new drug Mounjaro (tirzepatide ) wins US FDA approval

Blood sugar control drug Mounjaro has been granted US regulatory approval, giving type 2 diabetics another way to help keep their glucose levels in check.

Aurobindo Gets Hit With Another Form 483
Aurobindo Gets Hit With Another Form 483
Aurobindo Pharma has taken another hit from the FDA after an inspection of its oral drug manufacturing facility in Hyderabad, India, earlier this month resulted in a Form 483 report with six observ...
UCB Psoriasis Drug Will Need to Wait for US Approval
UCB Psoriasis Drug Will Need to Wait for US Approval
It won't be a happy weekend for UCB as the U.S. Food and Drug Administration issued a Complete Response Letter (CRL) to the Belgium-based company regarding its Biologics License Application (BLA) f...
PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE®
PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE®
PolarityTE, Inc. (Nasdaq: PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) designation to SkinTE under the Company's op...
FDA Approves Oral Form for the treatment of adults with amyotrophic lateral sclerosis (ALS)
FDA Approves Oral Form for the treatment of adults with amyotrophic lateral sclerosis (ALS)

FDA has approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis (ALS).

New data reinforces AstraZeneca and Sanofi’s nirsevimab as effective RSV immunisation
New data reinforces AstraZeneca and Sanofi’s nirsevimab as effective RSV immunisation

Nirsevimab is the first investigational immunisation designed to protect all infants across the RSV season with a single dose.

FDA Delays PDUFA Date for Amicus’ AT-GAA Therapy
FDA Delays PDUFA Date for Amicus’ AT-GAA Therapy
The FDA has extended by 90 days its Prescription Drug User Fee Act (PDUFA) decision dates for Amicus Therapeutics’ AT-GAA dual therapy, which includes a Biologics License Application (BLA) for c...
Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy
Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy
Stealth Biotherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochond...
Common steroids after 'long COVID' recovery may cut risk of death by up to 51%
Common steroids after 'long COVID' recovery may cut risk of death by up to 51%
Evidence continues to gather that "long COVID," that is, continued negative health impacts months after apparent recovery from severe COVID-19, is an important risk for some patients. ...
University of Aberdeen study finds diabetes almost doubles risk of COVID-19 death
University of Aberdeen study finds diabetes almost doubles risk of COVID-19 death

Researchers reviewed findings from 158 global studies to determine how COVID-19 affects people living with diabetes.

UK Study Shows Promising Data for Fourth COVID-19 Vaccine Shot
UK Study Shows Promising Data for Fourth COVID-19 Vaccine Shot
Participants in a small UK study who received a fourth dose of either the Pfizer-BioNTech COVID-19 vaccine, Comirnaty, or the Moderna COVID-19 vaccine, Spikevax, showed a strong immune response. ...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand